Cargando…
Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach
Developing new, more effective antibiotics against resistant Mycobacterium tuberculosis that inhibit its essential proteins is an appealing strategy for combating the global tuberculosis (TB) epidemic. Finding a compound that can target a particular cavity in a protein and interrupt its enzymatic ac...
Autores principales: | Ejalonibu, Murtala A., Ogundare, Segun A., Elrashedy, Ahmed A., Ejalonibu, Morufat A., Lawal, Monsurat M., Mhlongo, Ndumiso N., Kumalo, Hezekiel M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703488/ https://www.ncbi.nlm.nih.gov/pubmed/34948055 http://dx.doi.org/10.3390/ijms222413259 |
Ejemplares similares
-
Ni(2+) and Cu(2+) complexes of N-(2,6-dichlorophenyl)-N-mesityl formamidine dithiocarbamate structural and functional properties as CYP3A4 potential substrates
por: Oladipo, Segun D., et al.
Publicado: (2023) -
Allostery Inhibition of BACE1 by Psychotic and Meroterpenoid Drugs in Alzheimer’s Disease Therapy
por: Ugbaja, Samuel C., et al.
Publicado: (2022) -
Understanding the Hsp90 N-Terminal Dynamics: Structural and Molecular Insights into the Therapeutic Activities of Anticancer Inhibitors Radicicol (RD) and Radicicol Derivative (NVP-YUA922)
por: Magwenyane, Ayanda M., et al.
Publicado: (2020) -
Design of New Schiff-Base Copper(II) Complexes: Synthesis,
Crystal Structures, DFT Study, and Binding Potency toward Cytochrome
P450 3A4
por: Yusuf, Tunde L., et al.
Publicado: (2021) -
In Silico Drug Repurposing Approach: Investigation of Mycobacterium tuberculosis FadD32 Targeted by FDA-Approved Drugs
por: Ngidi, Nolwazi Thobeka Portia, et al.
Publicado: (2022)